Ovarian and adnexal tumors are a leading cause of morbidity and mortality, with many women lacking access to timely and accurate diagnosis. As Entrepreneur in Residence on Prof. Timmerman's team, I ensure statistical and AI decision support models are available to the gynecological oncology community at scale, in a regulatory-compliant way. I also support and grow our community with tools for learning & development, testing & accreditation, quality control, case sharing, and running our studies and clinical trials. And finally, I build out our software platform to enable routine use of AI methods for image analysis and clinical decision support, by recruiting high-quality study data at scale, with tools embedded in routine diagnostic practice.

Velsera connects healthcare and life sciences to help diagnostic and discovery partners deliver on promise of precision medicine—a continuous flow of knowledge between researchers, scientists and clinicians around the world, creating insights that radically improve human health.Bridging the product and commercial teams, the product marketing ensures product market fit (product strategy & roadmap, positioning, personas & messages, GTM & launch plans), informs strategy with deep market and customer insights (market analysis, competitive intel, voice of the customer), and enables the sales teams (scientific & sales collateral, KOLs & testimonials, early access, outreach). As a senior leader I support key strategic initiatives including product strategy, AI/ML strategy, and solution sales.

UgenTec uses explainable AI & software automation to optimize molecular diagnostics. From sample to result with smart software for the connected molecular lab. Automate your sample workflow, cut interpretation time in half, and get actionable lab intelligence. UgenTec is a global molecular laboratory software provider servicing molecular labs, assay providers and instrument partners across clinical diagnostics, pharma, crop science, and more.As Marketing director at UgenTec, I lead:- strategic marketing: innovation management, go-to-market strategy, technology evaluation, competitive analysis, launch campaigns, branding, messaging & positioning, partnership due diligence- Revenue growth & sales enablement: demand gen, lead gen, ABM, digital marketing, industry events & scientific conferences, complex customer solution design, RFP responses, prospect-specific sales collateral development, distributor success- scientific marketing: KOL management, peer-reviewed publications, scientific talks, customer testimonials, co-publications, thought leadership- product marketing: Voice of Customer, early access/co-development projects, functional requirements gathering, customer workflow analysis, post market surveillance- marketing tactics: web and social presence, inside sales, inbound/outbound, CMS, customer success, CRM workflows & automations

Within the Genomics Software group at Agilent Technologies, the Clinical Applications division develops innovative bioinformatics solutions that unlock the full potential of molecular diagnostics. Visit genomics.agilent.com to learn how we help genetics and pathology labs address their challenges in assay design, analysis, interpretation, and reporting.At Agilent, I lead an international team of product managers, product owners, solution designers and data scientists to manage the broad portfolio of software solutions within Agilent Genomics across assay design, genomic sequence alignment and calling for amplicon and capture NGS assays, instrument connectivity, sample tracking and workflow management, variant interpretation and clinical reporting for oncology and inherited disease, diagnostic decision support for joint molecular pathology and genomics analyses, data sharing initiatives and clinical knowledge base integration.Activities of note:- Consolidated the disparate software initiatives across genomics into a single brand, solution vision, and comprehensive software strategy and roadmap, across internal initiatives and acquisitions- Identified, negotiated, and integrated key data sources through licensing with academia, health systems, and commercial vendors – across oncology and inherited disease- Lead functional & software due diligence for several Genomics acquisition targets, and reported directly to the CEO for strategic projects including Smart Connected Lab and Diagnostic Cockpit- Rebranded former Cartagenia solutions into Agilent Alissa, and successfully integrated software into the Agilent Genomics portfolio, through bundling software and SureSelect, sales enablement, and activating the broader Agilent Genomics sales team on software sales

Cartagenia helped genetics labs and clinics interpret, report, and share genomic variants in a clinical diagnostic setting across cancer genomics, inherited disease, and prenatal diagnosis. Based on the machine learning and biomedical text embedding genotype-phenotype correlation methods I developed during my PhD, Cartagenia's SaaS platform allowed labs to build efficient variant assessment and reporting workfows and effectively communicate with their referring physicians.As a scientific founder, I built on my clinical diagnostic knowledge, scientific insights, a deep understanding of routine diagnostic lab workflows, and solution selling skills to drive revenue growth in European markets and build out a mature software and clinical decision support platform for genomic testing. Our family relocation from Europe to the US East Coast was both a personal adventure as well as a driver for revenue in the US to equal that in Europe within the year. I built out key partnerships with hospitals, labs, academia and private lab groups to establish our US footprint – with key collaborations with institutions like the NIH, Invitae, Jax, Mount Sinai, Genoptix, Geisinger, Sanford, and more. Cartagenia partnered with Agilent Technologies and was later acquired and successfully integrated into the Diagnostics and Genomics Group.

As a PhD student and later as a postdoctoral scientist, I developed biomedical text machine learning tools for genotype-phenotype correlation and routine clinical interpretation of genetic variation in inherited disease and cancer context. Beyond the theory and research, I created actionable tools to support diagnosis of rare genetic disease, which lead to international research collaborations, and has culminated in a spinoff company now servicing major hospitals and genetic labs worldwide with genetic diagnostic data management platform based on a cloud computing SaaS model, across clinical research, routine oncology dx, congenital disease, and prenatal diagnosis.

As a postdoctoral researcher at Leuven University, I transferred research results at the Bioinformatics team to concrete clinical applications in routine diagnostics at the University hospital. Based on the results of my PhD research and together with my partner in crime, we built a business plan, engaged first customers, secured seed funding, and built an initial team to foster the incorporation of Cartagenia as a spin-off.

As a visiting researcher I worked together with the SANGER Web Team (the ENSEMBL crew) and the Cytogenetics group of Nigel Carter to implement biomedical literature data mining tools for candidate gene prioritization based on human phenotype ontologies. This work lead to the extension of DECIPHER (https://decipher.sanger.ac.uk/) with tools to guide clinical interpretation of copy number variants in patients with rare genetic disorders.

Security Engineer and Project Manager at at BACOB, Artesia Services and later Dexia. In the early days of online banking, I was responsible for internet banking security, card transaction security, intranet security, corporate security auditing, implementation of internal systems security audit recommendations, crafting and communicating security policies, and both employee and customer security communication and marketing. I managed a complex internal content security project to streamline access management across the company wide intranet. I reviewed security protocols, proposed new policies to upper management, and participated in security aspects of partnership due diligence projects.